Tag Archives: celg

Juno-Celgene Deal Has Street Cautiously Optimistic

Shares of biotech startup Juno Therapeutics rose as much as 29% Tuesday, and closed up 15%, as analysts weighed in on its $1 billion deal with Celgene announced late Monday. Celgene (CELG) agreed to pay $150 million upfront and buy 9.1 million Juno Therapeutics (JUNO) shares at 93 each — more than double Monday’s closing price — for $850 million. In exchange, Celgene gets the option to license Juno’s two leading chimeric antigen receptor (CAR) T cell

Celgene Places Big Bet On Juno’s CAR-T Cell Therapy

Big-cap biotech Celgene (CELG) said late Monday that it’s investing more than $1 billion in a partnership with startup Juno Therapeutics (JUNO), sending the latter’s stock soaring 35% in after-hours trading. Celgene will buy 9.1 million Juno shares for $1 billion and has the option to buy up to 30% of Juno’s total stock over the course of the 10-year collaboration. It will also make an upfront payment of $150 million in cash. Celgene will be

Agios/Celgene Leukemia Drug Scores, But Stocks Fall

Biotech Agios Pharmaceuticals (AGIO) on Friday reported positive early-stage data on a blood-cancer drug it’s developing with Celgene (CELG), but its stock tumbled more than 10% as the response rate seemed to miss investor expectations. Agios said that out of 158 patients with acute myeloid leukemia (AML) and other advanced blood cancers taking AG-221, the response rate (tumor shrinkage) was 40%, while 16% went into complete remission. Agios also